Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND: Neoadjuvant T-DXd vs THP in HER2+ Early Breast Cancer
NCT06548178Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan in HER2-positive breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Pathological Complete Response at 1 year. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06548178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548178.